152 related articles for article (PubMed ID: 21283989)
1. Preparation, characterisation and entrapment of a non-glycosidic threitol ceramide into liposomes for presentation to invariant natural killer T cells.
Kaur R; Chen J; Dawoodji A; Cerundolo V; Garcia-Diaz YR; Wojno J; Cox LR; Besra GS; Moghaddam B; Perrie Y
J Pharm Sci; 2011 Jul; 100(7):2724-33. PubMed ID: 21283989
[TBL] [Abstract][Full Text] [Related]
2. Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants.
Hussain MJ; Wilkinson A; Bramwell VW; Christensen D; Perrie Y
J Pharm Pharmacol; 2014 Mar; 66(3):358-66. PubMed ID: 24251796
[TBL] [Abstract][Full Text] [Related]
3. Amide analogues of CD1d agonists modulate iNKT-cell-mediated cytokine production.
Wojno J; Jukes JP; Ghadbane H; Shepherd D; Besra GS; Cerundolo V; Cox LR
ACS Chem Biol; 2012 May; 7(5):847-55. PubMed ID: 22324848
[TBL] [Abstract][Full Text] [Related]
4. Subunit vaccines: distearoylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system.
McNeil SE; Rosenkrands I; Agger EM; Andersen P; Perrie Y
J Pharm Sci; 2011 May; 100(5):1856-65. PubMed ID: 21374619
[TBL] [Abstract][Full Text] [Related]
5. Non-glycosidic compounds can stimulate both human and mouse iNKT cells.
Jukes JP; Gileadi U; Ghadbane H; Yu TF; Shepherd D; Cox LR; Besra GS; Cerundolo V
Eur J Immunol; 2016 May; 46(5):1224-34. PubMed ID: 26873393
[TBL] [Abstract][Full Text] [Related]
6. Effective stimulation of invariant natural killer T cells by oligomannose-coated liposomes.
Ishii M; Kojima N
Int Immunopharmacol; 2013 Apr; 15(4):685-92. PubMed ID: 23535021
[TBL] [Abstract][Full Text] [Related]
7. Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells.
Silk JD; Salio M; Reddy BG; Shepherd D; Gileadi U; Brown J; Masri SH; Polzella P; Ritter G; Besra GS; Jones EY; Schmidt RR; Cerundolo V
J Immunol; 2008 May; 180(10):6452-6. PubMed ID: 18453560
[TBL] [Abstract][Full Text] [Related]
8. Cationic DDA/TDB liposome as a mucosal vaccine adjuvant for uptake by dendritic cells in vitro induces potent humoural immunity.
Qu W; Li N; Yu R; Zuo W; Fu T; Fei W; Hou Y; Liu Y; Yang J
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):852-860. PubMed ID: 29447484
[TBL] [Abstract][Full Text] [Related]
9. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses.
Davidsen J; Rosenkrands I; Christensen D; Vangala A; Kirby D; Perrie Y; Agger EM; Andersen P
Biochim Biophys Acta; 2005 Dec; 1718(1-2):22-31. PubMed ID: 16321607
[TBL] [Abstract][Full Text] [Related]
10. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.
Kitamura H; Iwakabe K; Yahata T; Nishimura S; Ohta A; Ohmi Y; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nishimura T
J Exp Med; 1999 Apr; 189(7):1121-8. PubMed ID: 10190903
[TBL] [Abstract][Full Text] [Related]
11. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
12. Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo.
Nordly P; Korsholm KS; Pedersen EA; Khilji TS; Franzyk H; Jorgensen L; Nielsen HM; Agger EM; Foged C
Eur J Pharm Biopharm; 2011 Jan; 77(1):89-98. PubMed ID: 20940050
[TBL] [Abstract][Full Text] [Related]
13. Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles.
Macho Fernandez E; Chang J; Fontaine J; Bialecki E; Rodriguez F; Werkmeister E; Krieger V; Ehret C; Heurtault B; Fournel S; Frisch B; Betbeder D; Faveeuw C; Trottein F
Int J Pharm; 2012 Feb; 423(1):45-54. PubMed ID: 21575695
[TBL] [Abstract][Full Text] [Related]
14. Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on bilayer properties, biodistribution, and immune responses.
Kaur R; Henriksen-Lacey M; Wilkhu J; Devitt A; Christensen D; Perrie Y
Mol Pharm; 2014 Jan; 11(1):197-207. PubMed ID: 24171445
[TBL] [Abstract][Full Text] [Related]
15. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.
Fujii S; Shimizu K; Smith C; Bonifaz L; Steinman RM
J Exp Med; 2003 Jul; 198(2):267-79. PubMed ID: 12874260
[TBL] [Abstract][Full Text] [Related]
16. Influence of trehalose 6,6'-diester (TDX) chain length on the physicochemical and immunopotentiating properties of DDA/TDX liposomes.
Kallerup RS; Madsen CM; Schiøth ML; Franzyk H; Rose F; Christensen D; Korsholm KS; Foged C
Eur J Pharm Biopharm; 2015 Feb; 90():80-9. PubMed ID: 25445301
[TBL] [Abstract][Full Text] [Related]
17. Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses.
Stolk DA; de Haas A; Vree J; Duinkerken S; Lübbers J; van de Ven R; Ambrosini M; Kalay H; Bruijns S; van der Vliet HJ; de Gruijl TD; van Kooyk Y
Front Immunol; 2020; 11():990. PubMed ID: 32536918
[TBL] [Abstract][Full Text] [Related]
18. Correlating liposomal adjuvant characteristics to in-vivo cell-mediated immunity using a novel Mycobacterium tuberculosis fusion protein: a multivariate analysis study.
Kastner E; Hussain MJ; Bramwell VW; Christensen D; Perrie Y
J Pharm Pharmacol; 2015 Mar; 67(3):450-63. PubMed ID: 25677402
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma.
Escribà-Garcia L; Alvarez-Fernández C; Tellez-Gabriel M; Sierra J; Briones J
J Transl Med; 2017 May; 15(1):115. PubMed ID: 28549432
[TBL] [Abstract][Full Text] [Related]
20. The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production.
Henriksen-Lacey M; Devitt A; Perrie Y
J Control Release; 2011 Sep; 154(2):131-7. PubMed ID: 21640145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
